Stock Research for AGIO

AGIO

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AGIO Stock Chart & Research Data

The AGIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AGIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AGIO Due diligence Resources & Stock Charts

The AGIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AGIO Detailed Price Forecast - CNN Money CNN View AGIO Detailed Summary - Google Finance
Yahoo View AGIO Detailed Summary - Yahoo! Finance Zacks View AGIO Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View AGIO Trends & Analysis - Trade-Ideas Barrons View AGIO Major Holders - Barrons
NASDAQ View AGIO Call Transcripts - NASDAQ Seeking View AGIO Breaking News & Analysis - Seeking Alpha
Spotlight View AGIO Annual Report - CompanySpotlight.com OTC Report View AGIO OTC Short Report - OTCShortReport.com
TradeKing View AGIO Fundamentals - TradeKing Charts View AGIO SEC Filings - Bar Chart
WSJ View Historical Prices for AGIO - The WSJ Morningstar View Performance/Total Return for AGIO - Morningstar
MarketWatch View the Analyst Estimates for AGIO - MarketWatch CNBC View the Earnings History for AGIO - CNBC
StockMarketWatch View the AGIO Earnings - StockMarketWatch MacroAxis View AGIO Buy or Sell Recommendations - MacroAxis
Bullish View the AGIO Bullish Patterns - American Bulls Short Pains View AGIO Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View AGIO Stock Mentions - StockTwits PennyStocks View AGIO Stock Mentions - PennyStockTweets
Twitter View AGIO Stock Mentions - Twitter Invest Hub View AGIO Investment Forum News - Investor Hub
Yahoo View AGIO Stock Mentions - Yahoo! Message Board Seeking Alpha View AGIO Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for AGIO - SECform4.com Insider Cow View Insider Transactions for AGIO - Insider Cow
CNBC View AGIO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AGIO - OTC Markets
Yahoo View Insider Transactions for AGIO - Yahoo! Finance NASDAQ View Institutional Holdings for AGIO - NASDAQ


Stock Charts

FinViz View AGIO Stock Insight & Charts - FinViz.com StockCharts View AGIO Investment Charts - StockCharts.com
BarChart View AGIO Stock Overview & Charts - BarChart Trading View View AGIO User Generated Charts - Trading View


Latest Financial News for AGIO

Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
Posted on Monday June 18, 2018

Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the initiation of the Phase 3 ACTIVATE trial evaluating AG-348, a first-in-class, selective, small molecule activator of the pyruvate kinase-R (PKR) enzyme. ACTIVATE is a randomized, placebo-controlled trial that will enroll approximately 80 adults with pyruvate kinase (PK) deficiency who do not receive regular blood transfusions. “AG-348 is the first potential treatment for PK deficiency that targets the underlying cause of a patient’s anemia and has demonstrated robust and sustained hemoglobin increases in adults with this disease who are not regularly transfused,” said Chris Bowden, M.D., chief medical officer of Agios.


Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason
Posted on Tuesday June 05, 2018

As Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closes at new highs, analysts are gushing over the company’s prospects. What is it about Agios stock  that has the experts bullish on the company? Markets speculated that Celgene Corporation (NASDAQ:CELG) would buy Agios or Jounce Therapeutics, Inc. (NASDAQ:JNCE) back in April.


New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
Posted on Monday June 04, 2018

-Safety Profile of Combination Therapies Consistent with Single Agent IDHm Inhibitors and Azacitidine-. -ORR of 78%, CR Rate of 44% and CR/CRi/CRp Rate of 65% in the Ivosidenib Arm; Molecular Clearance ...


Agios Pharmaceuticals (AGIO) Up 13.4% Since Earnings Report: Can It Continue?
Posted on Monday June 04, 2018

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.


Enter a stock symbol to view the stock details.